MedDataX Logo

Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis

NCT02162693 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2017-11-17

No results posted yet for this study

Summary

Current medication treatments for KOA aim to relieve inflammation and pain, but they do little to delay or reverse the disease progression and most medications have obvious side effects. When the conservative treatments are useless to patients and joint deformities and joint disfunction, the patients may require surgery. Although surgery of the joints can relieve the pain temporarily, long-term effect (over 10 years) is hard to achieve.

Conditions

  • Knee Osteoarthritis

Interventions

BIOLOGICAL

Mesenchymal progenitor cells

Administrated for intra-articular injection

BIOLOGICAL

Sodium Hyaluronate

Sponsors & Collaborators

  • RenJi Hospital

    collaborator OTHER

  • General Hospital of Chinese Armed Police Force

    collaborator UNKNOWN

  • Shanghai AbelZeta Ltd.

    lead INDUSTRY

Principal Investigators

  • Chunde Bao, MD · RenJi Hospital

  • Zhongwen Zhang, MD · General Hospital of Chinese Armed Police Force

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-05-31
Completion
2016-11-30

Countries

  • China

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162693 on ClinicalTrials.gov